- Report
- May 2024
- 208 Pages
Global
From €5237EUR$5,450USD£4,495GBP
- Report
- May 2024
- 88 Pages
Global
From €5381EUR$5,600USD£4,619GBP
- Report
- May 2024
- 168 Pages
Global
From €4756EUR$4,950USD£4,083GBP
- Report
- April 2024
- 183 Pages
Global
From €4708EUR$4,900USD£4,042GBP
- Report
- March 2021
- 44 Pages
Global
€21139EUR$22,000USD£18,146GBP
- Report
- December 2021
Global
From €4660EUR$4,850USD£4,000GBP
- Book
- April 2020
- 272 Pages
- Book
- June 2021
- 592 Pages
- Book
- April 2020
- 336 Pages
- Book
- April 2019
- 816 Pages
- Book
- July 2018
- 832 Pages
- Book
- September 2016
- 680 Pages
- Book
- May 2016
- 288 Pages
- Book
- October 2015
- 520 Pages
- Book
- October 2013
- 624 Pages
- Book
- October 2012
- 456 Pages
- Book
- April 2012
- 1272 Pages
- Book
- February 2012
- 496 Pages
- Book
- September 2010
- 424 Pages
- Book
- May 2009
- 354 Pages
The Hepatitis market is a subset of the larger Hepatology market, which focuses on the diagnosis, treatment, and prevention of liver diseases. Hepatitis is a viral infection that can cause inflammation of the liver, and can be caused by a variety of viruses, including hepatitis A, B, C, D, and E. Treatment for hepatitis can include antiviral medications, immunosuppressants, and interferon therapy. Vaccines are also available to prevent hepatitis A and B.
The Hepatitis market is a growing field, with a focus on developing new treatments and therapies to improve patient outcomes. Companies in the market include Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Novartis. Show Less Read more
